A Phase 4 interventional study of Clopidogrel and Ticagrelor in Plaque, Atherosclerotic, sponsored by CHEOL WHAN LEE, M.D., Ph.D. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-26.
Sponsored by CHEOL WHAN LEE, M.D., Ph.D · Phase 4, Interventional, and Treatment
Objectives: To compare the effects of clopidogrel versus ticagrelor on atherosclerotic plaque inflammation using serial FDG PET/CT imaging of carotid artery and ascending aorta.
Hypothesis: Thrombosis and inflammation are tightly linked rather than separate entities. Therefore, P2Y12 receptor inhibitors may have an anti-ischemic effect by inhibiting plaque inflammation, and ticagrelor may be superior in efficacy to clopidogrel.
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
This study's enrollment of 50 is close to the median of 50 across 2,437 interventional studies indexed under Inflammation.
Browse Inflammation studies →CHEOL WHAN LEE, M.D., Ph.D is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
clopidogrel: 75mg once a day
Drug: Clopidogrel
ticagrelor: 90mg twice a day
Drug: Ticagrelor
75mg once a day
90mg twice a day
change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest
Analyses of FDG activity will be quantified on common carotid arteries and ascending aorta of the aortic arch. Primary endpoint is change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest, known as a target-to-background ratio(blood-normalized standardized uptake value).
Time frame: 6months
Serial changes of high-sensitivity C-reactive protein
Time frame: 6months
Serial changes of lipid battery
lipid battery (total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol).
Time frame: 6months
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHEOL WHAN LEE, M.D., Ph.D